Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Up 841.9% in December

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 40,500 shares, an increase of 841.9% from the November 30th total of 4,300 shares. Based on an average trading volume of 171,400 shares, the days-to-cover ratio is presently 0.2 days.

Inhibitor Therapeutics Trading Up 19.5 %

Shares of INTI stock traded up $0.01 on Thursday, reaching $0.08. 2,000 shares of the stock were exchanged, compared to its average volume of 29,786. Inhibitor Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.14. The company has a market capitalization of $13.51 million, a price-to-earnings ratio of -7.84 and a beta of -0.61. The business’s 50 day moving average price is $0.08 and its 200 day moving average price is $0.08.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.